Abstract
Cancer in adolescents and young adults (AYA) represents a higher fraction of all cancer in countries that are still undergoing a demographic transition. Such countries tend to have much younger populations, and therefore unless they have a particularly low incidence of cancer in this age group, will have a higher burden of cancer (absolute number of cases with cancer) in AYA. Cancers in AYA are comprised of the tail end of the incidence curve of cancers that have their peak incidence, or occur almost exclusively in childhood, the beginning of the incidence curve of cancers that primarily affect the elderly, and a third set of cancers that have their peak incidence (or are at least common) in the AYA age group (e.g., testicular cancer, sarcomas, melanoma, thyroid cancer). Many, but not all, of these cancers require radiation or cancer surgery, but the poorest countries do not have a sufficient number of radiation therapy units and surgical oncologists, or indeed medical and pediatric oncologists, to deal with the burden of cancer they face. The AYA age group is particularly important, both with regard to their contribution to the economy now and in the future (the majority are in the “working” age-group defined as 15–64 years), as well as their important role in caring for their families. Moreover, some of these cancers are eminently curable with chemotherapy alone, and more could be cured by simply improving the efficiency of existing health services and providing education and training to both the public as well as oncologists and other specialists required for the care of AYA (although such individuals will not necessarily be exclusively concerned with this age group). Of particular importance is the detection and diagnosis of cancer patients at the earliest possible time in the course of their disease. Avoiding delays in initiating therapy, which are partly due to the poverty and lack of education of the public as well as to a failure on the part of primary health care providers to recognize the possibility of cancer, would lead not only to improved survival and less toxicity, but is likely to reduce the need for radiation as well as the cost of treatment. There are few good quality clinical trials that take place in the LMIC (in relationship to the extent of the existing cancer burden), and research training should be an integral component of capacity building. Research on the efficacy and toxicity of standardized treatment approaches that are either based on principles established in the HIC, or adapted from treatment protocols used in the HIC, would be a good place to begin, but health policy and multisectoral collaboration are essential if improved survival rates are to be achieved. Decisions will also need to be made regarding the treatment of diseases in which radiation or cancer surgery are important elements, when one or both of the latter are unavailable. Late effects are important in this young population in HIC, and protocol adaptations or design in LMIC should take into consideration the significant fraction of cured patients with late effects who were treated in HIC in an era where improving response and survival rates was the paramount consideration—the situation that applies today in less developed countries. Special adolescent units which better deal with psychological issues of young cancer patients are rare in LMIC and the psychosocial issues faced by adolescents are much less studied. Although survival is the first consideration, attention to psychosocial and financial issues may reduce existing delays in initiating therapy and also the fraction of patients that abandon therapy.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Memorial Fund Quarterly. 1971;29:509–38.
World Bank. How we classify countries. Available at http://data.worldbank.org/about/country-classifications
Human development index (HDI). United Nations Development Programme. Available at http://hdr.undp.org/en/statistics/hdi/
Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v2.0—cancer incidence and mortality worldwide:IARC CancerBase No 10. Lyon: International Agency for Research on Cancer, 2010. http://globocan.iarc.fr
World Health Organization. NCD Mortality 2008. Available at http://gamapserver.who.int/gho/interactive_charts/ncd/mortality/premature/atlas.html
Magrath I, Steliarova-Foucher E, Epelman S, et al. Improving cancer care for children and young people 2. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14(3):e104–16.
Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:323–9.
Kremer LC, Mulder RL, Oeffinger KC, et al. International Late Effects of Childhood Cancer Guideline Harmonization Group. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013;60:543–9.
Jairam V, Roberts KB, Yu JB. Historical trends in the use of radiation therapy for pediatric cancers: 1973–2008. Int J Radiat Oncol Biol Phys. 2013;85:e151–5.
Patnayak R, Rambabu DV, Jena A, et al. Rare case of blastemal predominant adult Wilms’ tumor with skeletal metastasis case report and brief review of literature. Indian J Urol. 2012;28:447–9.
Dobson J. Percivall Pott. Ann R Coll Surg Engl. 1972;50:54–65.
Ngoma T, Adde M, Durosinmi M, et al. Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease. Brit J Haematol. 2012;158:749–62.
Cavdar CO, Gozdasoglu S, Yavuz G, et al. Burkitt’s lymphoma between African and American types in Turkish children in clinical, viral (EBV) and molecular studies. Med and Ped Onc. 1993;21:36–42.
Mbulaiteye SM, Anderson WF, Bhatia K, et al. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973–2005. Int J Cancer. 2010;126:1732–9.
Bleyer WA. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol. 2002;38:1–10.
Fernandez CV, Barr RD. Adolescents and young adults with cancer: An orphaned population. Paediatr Child Health. 2006;11:103–6.
Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011;105:S77–81.
West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006;94:1751–8.
Death from Hepatocellular Carcinoma in the United States, 1999–2006. J Stud Alcohol Drugs. 2011; 72: 892–902.
Ramot B, Magrath IT. Hypothesis: the environment is a major determinant of the immunological sub-type of lymphoma and acute lymphoblastic leukemia in children. Br J Haem. 1982;50:183–9.
•• Wu QJ, Vogtmann E, Zhang W, Xie L. Cancer incidence among adolescents and young adults in urban Shanghai, 1973–2005. PLoS One. 2012;7:e42607. One of the few published articles on AYAs in LMIC. This publication demonstrates differences in the cancer subtypes in AYAs in Shanghai, China, compared to the spectrum in high income countries (in 2011, China was an UMIC), and the trends over time (see figure 11).
Duan C, Wang W, Xie Q. Review article: fabrication of nanofluidic devices. Biomicrofluidics. 2013;7:26501.
Potterton L. Access to affordable radiotherapy. IAEA Bull. 2010;52:10–1.
Olweny CLM, Katangole-Mbidde E, Khre. Childhood Hodgkin’s disease in Uganda - A ten year experience. Cancer. 1978;42:787–92.
•• Richard Sullivan, Jerzy R Kowalczyk, Bharat Agarwal, Ruth Ladenstein et al. Improving cancer care for children and young people 4; New policies to address the global burden of childhood cancers, Lancet Oncol. 2013 Mar, 14e125-35. This article provides a broad overview of various policy issues relating to the care of children and young people with cancer.
Patte C, Auperin A, Gerrard M, et al. For the FAB/LMB96 international study committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.
Compliance with Ethics Guidelines
Conflict of Interest
Ian Magrath declares no potential conflict of interest.
Sidnei Epelman declares no potential conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Magrath, I., Epelman, S. Cancer in Adolescents and Young Adults in Countries with Limited Resources. Curr Oncol Rep 15, 332–346 (2013). https://doi.org/10.1007/s11912-013-0327-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11912-013-0327-3